New York, USA – December 27, 2021 – With the designation of the SARS-CoV-2 variant of concern, named Omicron, by WHO in November, researchers in South Africa and around the world are conducting studies to better understand mutations in Omicron. As available information is limited, the potential impact of this variant on existing countermeasures, including vaccines, has not been confirmed yet. Creative Biolabs, the leading biotech company engaged in antiviral drug discovery and vaccine development for years, points out that vaccines remain critical to reducing severe disease and death. This company enhances its vaccine development services for SARS-CoV-2 to consolidate the performance of current vaccines and antiviral drugs, such as anti-SARS-CoV-2 monoclonal antibodies to better against variants.
Supported by cutting-edge technical technologies and competent researchers, Creative Biolabs has established a comprehensive vaccine development system involving the identification of potential targets, analysis of the immune response, and assessment in an infectious challenge model.
The vaccine design platform using in silico models at Creative Biolabs has built-in epitope screening tools that can identify potential epitopes in protein vaccine targets. With sequence information, structural bioinformatics, and experimental data, it’s possible to identify conserved regions in multiple SARS-CoV-2 strains so that vaccines can be designed with maximum coverage.
As vaccines remain the most effective method to defend against severe disease and deaths caused by SARS-CoV-2 and its variants, developing new vaccines both at preclinical and clinical stages is of vital importance. Creative Biolabs expands services for the development of different vaccine types, including live attenuated and killed vaccine development service, recombinant subunit vaccine development service, mRNA vaccine development service, and SARS-CoV-2 MVA vectored vaccine services.
With the emergence of Delta and Omicron variants, the need for developing universal vaccines to address evolving SARS-CoV-2 variants is growing even though current vaccines remain effective. Confronted with the complexity, expense, and high risks of vaccine development, Creative Biolabs makes use of various analytical techniques to qualify SARS-CoV-2 vaccines. The analysis and qualification of SARS-CoV-2 vaccines will characterize biophysical properties of antigens, study the antigen-adjuvant interactions, assess stabilizers, evaluate product contact materials, and monitor real-time and accelerated stability.
To learn more as to how Creative Biolabs advances innovative COVID-19 vaccine development with modern technology and practical experience, please visit https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs, Inc. is a leading antibody-based biotech company offering various products, such as recombinant proteins, antibodies, and test kits to researchers for anti-COVID-19 purposes. To advance drug and vaccine development, this company expands high-quality CRO services in the field of antivirals discovery, vaccine design, preclinical evaluation, diagnostic immunoassays development for better meeting the standards of quality, safety, and regulatory.